Literature DB >> 14673207

Role of cdk5 in the pathogenesis of Alzheimer's disease.

Lit-Fui Lau1, Michael K Ahlijanian.   

Abstract

Alzheimer's disease (AD) is characterized by two pathological hallmarks, namely, senile plaques and neurofibrillary tangles (NFTs). The former are mainly composed of amyloid-beta peptides (Abeta) while the latter consists mainly of filaments of hyperphosphorylated tau. Cyclin-dependent kinase 5 (cdk5) has been implicated not only in the tangle pathology, but recent data also implicate cdk5 in the generation of Abeta peptides. Since both Abeta peptides and NFTs are believed to play a role in neurodegeneration in AD, this proline-directed serine/threonine protein kinase is likely to contribute to the pathogenesis of AD. In vitro and in vivo animal data demonstrate the ability of cdk5 to induce phosphorylation and aggregation of tau, and NFT deposition and neurodegeneration. Findings from AD brain samples also show an elevated cdk5 activity and conditions that support the activation of cdk5. Evidence for the role of cdk5 in regulating Abeta production is just emerging. The mechanisms for this potentially damaging activity of cdk5 are largely unknown although amyloid precursor protein and presenilin-1 are both cdk5 substrates. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14673207     DOI: 10.1159/000074622

Source DB:  PubMed          Journal:  Neurosignals        ISSN: 1424-862X


  26 in total

1.  Drug discovery for Alzheimer's disease: the end of the beginning.

Authors:  Lorenzo M Refolo; Howard M Fillit
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations.

Authors:  Bing Zhang; Zhou Cheng Su; Tong Earn Tay; Vincent B C Tan
Journal:  J Mol Model       Date:  2009-12-15       Impact factor: 1.810

3.  Docking and 3D-QSAR modeling of cyclin-dependent kinase 5/p25 inhibitors.

Authors:  Zaheer Ul Haq; Reaz Uddin; Lam Kok Wai; Abdul Wadood; Nordin Haji Lajis
Journal:  J Mol Model       Date:  2010-08-05       Impact factor: 1.810

4.  Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.

Authors:  Bing Zhang; Vincent B C Tan; Kian Meng Lim; Tong Earn Tay; Shulin Zhuang
Journal:  J Mol Model       Date:  2006-06-13       Impact factor: 1.810

5.  Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators.

Authors:  Bing Zhang; Vincent B C Tan; Kian Meng Lim; Tong Earn Tay
Journal:  J Comput Aided Mol Des       Date:  2006-10-13       Impact factor: 3.686

6.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

Review 7.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

8.  Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease.

Authors:  Takahide Kaji; Barry Boland; Tatjana Odrljin; Panaiyur Mohan; Balapal S Basavarajappa; Corrinne Peterhoff; Anne Cataldo; Anna Rudnicki; Niranjana Amin; Bing Sheng Li; Harish C Pant; Basalingappa L Hungund; Ottavio Arancio; Ralph A Nixon
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.

Authors:  Wei Wang; Xiaoning Cao; Xiaolei Zhu; Yongliang Gu
Journal:  J Mol Model       Date:  2013-03-23       Impact factor: 1.810

10.  p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity.

Authors:  Lingyan Zhang; Wen Liu; Karen K Szumlinski; John Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.